REGN vs. VRTX, GSK, SNY, BMY, ZTS, PFE, TAK, ABT, RPRX, and BGNE
Should you be buying Regeneron Pharmaceuticals stock or one of its competitors? The main competitors of Regeneron Pharmaceuticals include Vertex Pharmaceuticals (VRTX), GSK (GSK), Sanofi (SNY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Pfizer (PFE), Takeda Pharmaceutical (TAK), Abbott Laboratories (ABT), Royalty Pharma (RPRX), and BeiGene (BGNE). These companies are all part of the "pharmaceutical preparations" industry.
Regeneron Pharmaceuticals (NASDAQ:REGN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.
Vertex Pharmaceuticals received 62 more outperform votes than Regeneron Pharmaceuticals when rated by MarketBeat users. Likewise, 75.65% of users gave Vertex Pharmaceuticals an outperform vote while only 66.59% of users gave Regeneron Pharmaceuticals an outperform vote.
Vertex Pharmaceuticals has a net margin of 39.46% compared to Regeneron Pharmaceuticals' net margin of 29.45%. Vertex Pharmaceuticals' return on equity of 23.08% beat Regeneron Pharmaceuticals' return on equity.
Regeneron Pharmaceuticals currently has a consensus target price of $989.36, indicating a potential upside of 2.13%. Vertex Pharmaceuticals has a consensus target price of $432.18, indicating a potential downside of 4.29%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than Vertex Pharmaceuticals.
In the previous week, Vertex Pharmaceuticals had 18 more articles in the media than Regeneron Pharmaceuticals. MarketBeat recorded 30 mentions for Vertex Pharmaceuticals and 12 mentions for Regeneron Pharmaceuticals. Vertex Pharmaceuticals' average media sentiment score of 0.79 beat Regeneron Pharmaceuticals' score of 0.75 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.
Regeneron Pharmaceuticals has higher revenue and earnings than Vertex Pharmaceuticals. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 7.5% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Regeneron Pharmaceuticals has a beta of 0.17, meaning that its share price is 83% less volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500.
Summary
Vertex Pharmaceuticals beats Regeneron Pharmaceuticals on 11 of the 18 factors compared between the two stocks.
Get Regeneron Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding REGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Regeneron Pharmaceuticals Competitors List
Related Companies and Tools
